<DOC>
	<DOCNO>NCT01150344</DOCNO>
	<brief_summary>Riamet® Malarone® recommend first line treatment uncomplicated malaria France , accord French consensus Conference revise 2007 treatment import malaria . The aim study compare tolerance efficacy Malarone® Riamet® treatment uncomplicated import malaria determine clinical parasitological predictive factor associate less effectiveness . It 's multicentric , randomise study adult uncomplicated malaria . Treatment administer 3 day , patient follow 28 day , evaluate therapeutic evolution . 640 patient include among 15 centre .</brief_summary>
	<brief_title>Evaluation Riamet® Versus Malarone® Treatment Uncomplicated Malaria</brief_title>
	<detailed_description>Background : RIAMET® Malarone® recommend first line treatment uncomplicated malaria France , accord French consensus Conference revise 2007 treatment import malaria . Today randomize control trial ( RCT ) compare treatment available either tolerance efficacy especially field import malaria . Malarone® , atovaquone+proguanil combination , become last year prescribe treatment adult indication France . With Malarone® , therapeutic failure rare , digestive side effect observe , vomit , possibly lead use second line treatment . Riamet® , artemether+lumefantrine combination , available France since July 2007 , largely used endemic area ( CO-ARTEM ) . A good tolerance efficacy report study perform endemic area . Both antimalarial take 3-days treatment period , day Malarone® , twice day Riamet® , suppose affect observance , one hand . On hand , parasitological cure rate apyrexia occur fast RIAMETt® Malarone® . Primary objective : compare tolerance et efficacy Malarone® RIAMET® treatment uncomplicated import malaria . Secondary objective : determine clinical parasitological predictive factor associate less effectiveness . Primary outcome : Number case second line treatment use either intolerance lack effectiveness within 28 day diagnosis malaria . Secondary outcome : parasitological cure rate J3 , fever clearance , digestive tolerance , number relapse . Design : Multicentric , open-label , randomize , control trial superiority adult uncomplicated malaria contraindication oral treatment . Treatment administer 3 day , patient follow 28 day , accord national recommendation , evaluate therapeutic evolution . 640 patient include within 36 month . Recruitment take place among 15 correspond centre Malaria National Reference Centre . Inclusion criterion : subject age 18 , back endemic area positive diagnosis Plasmodium falciparum microscopic blood ( thin thick film ) examination , able come back J3 , J7 J28 , consent participate . Non inclusion criterion : pregnancy , ECG abnormality , contraindication treatment , previous anti-malaric treatment within 30 day ( HALOFANTRIN ) 48 hour ( antimalarial treatment ) . Sample size justification : consider 13 % patient Malarone® treat second line treatment , 300 patient per group would necessary achieve relative reduction 50 % patient treated second line treatment ( i.e . 6,5 % ) RIAMET® group , 80 % statistical power type I error rate take 0,05 . Considering 5 % patient lose follow , 640 patient include . Perspectives : data help define best 1st line treatment uncomplicated malaria .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<mesh_term>Atovaquone , proguanil drug combination</mesh_term>
	<criteria>subject age 18 , back endemic area positive diagnosis Plasmodium falciparum microscopic blood ( thin thick film ) examination , absence severe manifestation accord WHO definition severe falciparum malaria EXCLUSION CRITERIA : pregnancy , ECG abnormality , contraindication treatment , previous antimalaric treatment within 30 day , unable come back J3 , J7 J28 , unwilling consent participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Multicentric study</keyword>
	<keyword>Antimalarial</keyword>
	<keyword>P. falciparum</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Failures</keyword>
	<keyword>Malarone</keyword>
	<keyword>RIAMET</keyword>
</DOC>